When compared with placebo, vunakizumab is a safe and efficacious treatment for moderate to severe plaque psoriasis among adults.

And beyond the physical symptoms, plaque psoriasis also frequently has negative effects on mental health and alters the lifestyle of those living with it. Here are five ways that this skin condition ...

Medically reviewed by Casey Gallagher, MD Psoriasis of the hands and feet, known as palmoplantar psoriasis, is an inflammatory autoimmune disorder that causes scaly, itchy skin patches on the palms ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments," said Samit ...

The efficacy and safety of risankizumab remains similar across racial and ethnic groups of patients with moderate to severe plaque psoriasis.

Johnson & Johnson recently rolled out a TV ad that takes aim at a major disparity in dermatology: the fact that people of ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Thera | Eli Lilly has dropped the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the ...

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.

Tremfya is approved for the treatment of adults with moderate to severe plaque psoriasis who may benefit from systemic therapy or phototherapy. The views and opinions expressed herein are the ...

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement ...

"The results from this study are aligned with our commitment to elevate the standard of care for the millions of adults impacted by moderate-to-severe plaque psoriasis, many of whom are currently ...